Viral vectors and packaging cell lines
AssigneeUmoja Biopharma, Inc.
InventorsAndrew Scharenberg, Laurie Beitz
Life of this patent
Estimating the term…
Abstract
The disclosure relates generally to nucleic acid vectors and packaging cell lines for in vivo expansion of T-cells. More particularly, the disclosure relates to direct intratumoral injection of a lentiviral vector adapted for transduction and drug-mediated expansion of tumor-infiltrating lymphocytes in vivo.
Claims22
A lentiviral particle for activating and efficiently transducing T cells, comprising a nucleic acid sequence encoding a small molecule controllable T-cell/NK-cell activation receptor, the nucleic acid sequence operatively linked to a promoter, wherein the T-cell/NK-cell activation receptor is capable of being activated by the small molecule;
- wherein the T-cell/NK-cell activation receptor comprises two polypeptide chains that comprise extracellular domains that bind the small molecule, and wherein the two polypeptide chains each comprise a transmembrane domain and an intracellular cytokine receptor signaling domain;
- and
- wherein the lentiviral particle further comprises a viral surface comprising an anti-CD3 antibody or scFv.
Dependencies are inferred from the claim text.